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by liver resection in patients with initial local failure. On the
other hand, another randomized controlled trial in larger num-
bers of patients reported that liver resection was signiﬁcantly
more advantageous [5]. Thus, it cannot be simply concluded
that liver resection and RFA are of similar effectiveness for
the treatment of small HCC. To answer the question whether
liver resection is superior to RFA or not, a nationwide random-
ized controlled trial involving 600 patients is now ongoing in
Japan [6].
We should estimate treatment outcomes for early HCC from
the stand point of biological characteristics, which differ from
those of other types of cancers, including prostate cancer. Our
experience with patients with treated and untreated early HCC
suggests that early HCC pathologically deﬁnable as cancer might
clinically be a precancerous lesion. Therefore, the good outcomes
obtained by RFA for small HCCs that may include early HCC are
likely to be overestimated by lead-time bias.
Taken together, we advocate that early HCC is not a life-
threatening disease and, therefore, both liver resection and RFA
are unnecessary treatments for early HCC that cannot be justiﬁed,
regardless of minimal invasiveness or lower morbidity.Conﬂict of interest
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5.9 mg/dl. Boceprevir was stopped at that time. During the total
course of therapy, the patient never developed neutropaenia, with
a neutrophilic count that never fell below 0.75 G/L. The patient did
not complain of fever or coughing. Details of the antiviral therapy
are shown in Fig. 1. Because the patient missed a regular control-
date appointment at week 21, another appointment was set for
four days later. He died one day after the appointment was set.
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Fig. 1. Course of haemoglobin, leucocytes, neutrophilic count (ANC) and viral
load (log10) during antiviral treatment. Administration of erythropoietin and
packed red blood cells is shown according to time.To the Editor:
Drug users are a high-risk group for contracting infectious dis-
eases like tuberculosis (TB), HIV, hepatitis B (HBV), and hepatitis
C (HCV). The prevalence of latent tuberculosis infection in drug
users varies from 10% to 59%, and the prevalence of chronic
HCV infection in drug users ranges from 25% to 75% [1].
The standard of care for chronic HCV consists of pegylated
interferon (PegIFN), ribavirin, and boceprevir or telaprevir in
genotype (GT) 1 patients [2]. These drugs have complex immuno-
modulatory and antiproliferative effects, which can lead to alter-
ations in the cytokine cascade [3,4].
A 33-year-old white male former drug user and prison inmate
was willing to undergo antiviral treatment for HCV after jail
release. He participated in an opioid maintenance program and
had PCR-proven, treatment-naive, chronic hepatitis C infection,
genotype 1a, IL28B polymorphism CT. HBV and HIV co-infections
were excluded before starting therapy. Active pulmonary TB
infection was ruled out by a normal chest radiograph.
Antiviral HCV therapy started with PegIFN (180 lg/wk) and a
weight-based dose of ribavirin (1000 mg/d). Because the patient
did not achieve a rapid virological response, boceprevir (2.400
mg/d) was added at week 5. HCV RNA fell to undetectable levels
at week 8 and remained negative during subsequent evaluations.
During therapy, this patient developed grade IV anaemia, and
ribavirin was thus reduced and later completely stopped according
to labelling. In addition, erythropoietin and packed red blood cells
were administered, but the haemoglobin level fell to a low level of
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An autopsy was performed, with the following ﬁndings:
noticeable excavation of the right lung with green–grey necrotic
tissue masses and disseminated focal necrosis in both lungs.
Histological examination of tissue samples showed gangre-
nous pneumonia with focal caseous necrosis without epitheloid
or giant cell formations. Positive Ziehl–Neelsen-based staining
for acid-fast rod bacteria (AFB) in the lung tissue substantiated
the presumed diagnosis of severe lung tuberculosis (Fig. 2).
Further investigations showed positive Ziehl-Neelsen staining
for AFB in gastric contents as well as in urine. Mycobacterium
tuberculosis DNA was detected in lung tissue and in gastric ﬂuid
via PCR. Because of putrefaction onset and contamination by other
microorganisms, a PCR analysis of a blood sample was
unsuccessful.
Taking into consideration the asymptomatic course and the
AFB-associated gangrenous pneumonia, in combination with
the evidence of M. tuberculosis DNA and positive Ziehl–Neelsen
staining in body ﬂuids, we concluded that antiviral triple therapy
suppressed the immune system, resulting in lethal TB infection
with peracute TB sepsis (Landouzy sepsis).
To our knowledge, this case is the ﬁrst description of TB sepsis
and death during triple therapy. Only a few clinical cases of TB in
patients undergoing HCV antiviral therapy have been reported
[5]. Antiviral HCV therapy is considered to suppress the immune
system and may lower CD4+ cell function, leading to increased
risk for infections [3,4,6–8].
Babudieri et al. suggested screening high-risk patients using
the tuberculin skin test (TST) or QuantiFERON TB In-Tube Test.
Positive test results from one of these methods do not, however,
necessarily indicate an active or latent TB infection; the Quanti-
FERON test can give positive results even after successful treat-
ment of TB. If results are positive, a chest radiograph should be
taken, and if TB infection is suspected, the patient should receive
anti-TB chemoprophylaxis prior to HCV antiviral treatment.
Thus far, the international guidelines for the management of
TB infection offer no recommendation regarding TB screening
using the QuantiFERON test or TST [2,9]. Physicians prescribing
antiviral HCV therapy should be aware of the risk of latent TB
infection, exacerbation, and de novo infection. Screening for
latent TB could be an option in high-risk patients like drug users
and prison inmates [10]. In this case, we performed a chest radio-
graph to exclude the main manifestation of TB, which is pulmon-
ary TB. In case of a suspicious chest radiograph at any time or
clinical symptoms during therapy, further investigations using
the QuantiFERON, TST, and/or M. tuberculosis PCR analysis should
be performed.
Taking into consideration the unsuspicious chest radiograph,
we infer from the autopsy ﬁndings that the patient had a fulmin-
ant primary infection due to the altered immune system during
antiviral therapy, although reactivation of a former TB infection
cannot be excluded.
Careful clinical evaluation and repeated chest radiographs
could be an option for timely detection of TB infections in high-
risk populations. Additionally, the need to perform TST or the
QuantiFERON TB In-Tube Test in high-risk patients prior to HCV
antiviral therapy should be considered.
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Fig. 2. Positive Ziehl–Neelsen-based staining for acid-fast rod bacteria (AFB)
in the lung tissue.
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